Evidence map›Paper›PMID 36056446›Full record

ArticleClinical epigenetics2022

Researcher perspectives on ethics considerations in epigenetics: an international survey.

Charles Dupras, Terese Knoppers, Nicole Palmour, Elisabeth Beauchamp, Stamatina Liosi, Reiner Siebert, Alison May Berner, Stephan Beck, Ian Charest, Yann Joly

Abstract read
In one paragraph

Article in Clinical epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. EpiATLAS - a reference for human epigenomic research.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charles DuprasCentre of Genomics and Policy, McGill University, 740, Avenue Dr. Penfield, Suite 5200, Montreal, QC, H3A 0G1, Canada. charles.dupras@umontreal.ca.ORCID 0000-0002-9194-3252
Terese KnoppersCentre of Genomics and Policy, McGill University, 740, Avenue Dr. Penfield, Suite 5200, Montreal, QC, H3A 0G1, Canada.ORCID 0000-0001-8912-1906
Nicole PalmourCentre of Genomics and Policy, McGill University, 740, Avenue Dr. Penfield, Suite 5200, Montreal, QC, H3A 0G1, Canada.ORCID 0000-0002-4163-9105
Elisabeth BeauchampCentre of Genomics and Policy, McGill University, 740, Avenue Dr. Penfield, Suite 5200, Montreal, QC, H3A 0G1, Canada.ORCID 0000-0002-1478-0699
Stamatina LiosiCentre for Health Ethics and Law, University of Southampton, Building 4, Highfield, Southampton, SO17 1BJ, UK.ORCID 0000-0001-7928-5106
Reiner SiebertInstitute of Human Genetics, Ulm University, Albert-Einstein-Allee 11, 89081, Ulm, Germany.ORCID 0000-0002-6492-5323
Alison May BernerBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 5PZ, UK.ORCID 0000-0002-1132-0275
Stephan BeckUniversity College London (UCL) Cancer Institute, 72 Huntley Street, London, WC1E 6BT, UK.ORCID 0000-0001-5290-2151
Ian CharestDepartment of Psychology, Université de Montréal, 90, Avenue Vincent-d'Indy/Boulevard Édouard-Montpetit, Montréal, QC, H2V 2S9, Canada.ORCID 0000-0002-3939-3003
Yann JolyCentre of Genomics and Policy, McGill University, 740, Avenue Dr. Penfield, Suite 5200, Montreal, QC, H3A 0G1, Canada.ORCID 0000-0002-8775-2322

Funding

CIHR CEE-151618CIHR MFE-152574
6 · The paper itself

Abstract

Over the past decade, bioethicists, legal scholars and social scientists have started to investigate the potential implications of epigenetic research and technologies on medicine and society. There is growing literature discussing the most promising opportunities, as well as arising ethical, legal and social issues (ELSI). This paper explores the views of epigenetic researchers about some of these discussions. From January to March 2020, we conducted an online survey of 189 epigenetic researchers working in 31 countries. We questioned them about the scope of their field, opportunities in different areas of specialization, and ELSI in the conduct of research and knowledge translation. We also assessed their level of concern regarding four emerging non-medical applications of epigenetic testing-i.e., in life insurance, forensics, immigration and direct-to-consumer testing. Although there was strong agreement on DNA methylation, histone modifications, 3D structure of chromatin and nucleosomes being integral elements of the field, there was considerable disagreement on transcription factors, RNA interference, RNA splicing and prions. The most prevalent ELSI experienced or witnessed by respondents were in obtaining timely access to epigenetic data in existing databases, and in the communication of epigenetic findings by the media. They expressed high levels of concern regarding non-medical applications of epigenetics, echoing cautionary appraisals in the social sciences and humanities literature.

Indexed as

DNA MethylationEpigenomicsHumansSurveys and QuestionnairesConduct of researchDirect-to-consumer testingELSIEpigeneticsEthicsForensicsImmigrationKnowledge translationLife insurance

Identifiers

PMID36056446
PMCPMC9440515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.